Trials / Completed
CompletedNCT00727753
VEGF-antagonism and Endothelial Function in Age-related Macular Degeneration (AMD)
Effects of Vascular Endothelial Growth Factor Antagonism With Ranibizumab or Bevacizumab in Patients With Neovascular Macular Degeneration
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 54 (actual)
- Sponsor
- University of Zurich · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the effects of 2 intravitreal injections with Ranibizumab or Avastin on endothelial function in subjects with neovascular macular degeneration compared to patients with dry AMD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ranibizumab | ranibizumab (0.5 mg) will be injected intraocular |
| DRUG | Bevacizumab | Bevacizumab (1.25 mg) will be injected intraocular |
| OTHER | No treatment | No treatment |
Timeline
- Start date
- 2008-07-01
- Primary completion
- 2012-12-01
- Completion
- 2013-10-01
- First posted
- 2008-08-04
- Last updated
- 2015-05-28
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT00727753. Inclusion in this directory is not an endorsement.